Jiajian Bio Completes RMB 100 Million Series B Financing to Advance Development and Commercialization of Multiple Gene Testing Products

VCBeat (WeChat: vcbeat) has learned that Guangzhou Jiajian Biotechnology Co., Ltd. announced the successful completion of its RMB 100 million Series B financing round. The round was led by E Fund Capital, with existing investor Legend Capital making additional investments. Previously, Jiajian Biotechnology had attracted investment from multiple institutions, including Guochuang Kaiyuan, Legend Capital, and Shiyu Capital, completing its Series A financing in 2019.

Guangzhou Jinqirui Biotechnology Co., Ltd., a subsidiary of Guangzhou Jiajian Biotechnology Co., Ltd., serves as the operational entity for Jiajian Biotechnology’s in vitro diagnostics (IVD) business. As a high-tech enterprise integrating research and development, manufacturing, sales, and after-sales services of precision medicine IVD products, it is committed to providing molecular diagnostic solutions with distinct clinical value to support the construction of China’s precision medicine system.

In early 2020, the KM MiniSeqDx-CN, jointly developed by Kingcare and Illumina, received approval from the National Medical Products Administration (NMPA) for market launch. Leveraging this milestone, the company achieved significant progress in revenue market share, technological R&D, and product registration. This round of financing will be used to further strengthen Kingcare Bio’s R&D innovation and introduction/transformation of multiple genetic testing products related to tumor companion diagnostics, pathogenic microorganisms, and genetic diseases; accelerate the registration and filing of its IVD products; and promote the deployment and expansion of Kingcare’s market channels, thereby bringing a broader and richer portfolio of precision medicine in vitro diagnostic products to clinical application more rapidly to benefit patients.

KM MiniSeqDx-CN Gene Sequencer

Wang Hao, Head of Healthcare Industry, E Fund Capitalstated: “Jinqirui is an outstanding IVD company. We believe that the major trend toward precision medicine in vitro diagnostics has been firmly established. We are optimistic about Jinqirui’s founding team, which boasts a profound cultural heritage, extensive industry experience, and deep market insight. We fully endorse Jinqirui’s unwavering commitment to advancing precision molecular diagnostics through localized in-hospital implementation, and we are delighted to witness the company’s rapid development since its inception. We are confident that, under the leadership of Dr. Hu Zhaohui, Mr. Liu Jun, and the entire team, the company will achieve substantial growth. It is our honor to participate in Jinqirui’s future journey.”

Legend Capital Managing Director Wang JunfengHe stated, “Genetic testing is a key investment focus for Legend Capital. The outbreak of the COVID-19 pandemic has accelerated public awareness of genetic testing for pathogenic microorganisms. Jinqirui is a company committed to innovation and dedicated to addressing clinical pain points and needs. The Jinqirui team demonstrates strong execution capabilities, having achieved critical milestones on schedule despite the challenges posed by the pandemic this year. Legend Capital has been supporting Jinqirui since its early stages. We are delighted to see Jinqirui gain favor from more prestigious investment institutions, allowing capital to jointly drive further growth for both the industry and the company.”

Dr. Hu Zhaohui, Chairman, and Mr. Liu Jun, General Manager, the two founders of JinqiruiHe stated, “We are delighted to welcome E Fund Capital, such a professional strategic investor, and we sincerely thank our existing shareholder, Legend Capital, for its continued support. This will greatly assist Jin Qirui in building a leading platform for in vitro diagnostic (IVD) products. Jin Qirui will focus on the in-hospital deployment of molecular diagnostic IVD products, represented by next-generation sequencing (NGS), providing hospitals with automated, cost-effective, and highly accessible comprehensive molecular diagnostic solutions. Jin Qirui will continuously improve its molecular diagnostic product portfolio for pathogenic microorganisms, achieving comprehensive coverage across high-end, mid-range, basic, and rapid-testing segments; strengthen R&D and innovation capabilities in areas such as personalized tumor therapy and genetic diseases; closely align with patients’ clinical needs to provide hospitals with more compliant IVD molecular diagnostic products; and create value for society, customers, employees, and shareholders.”